Today, John Lee, Chief Executive of the Hong Kong Special Administrative Region, graced the Asian Medical and Health Summit Forum 2026 with his presence. He highlighted that the national '15th Five-Year Plan' has put forward initiatives aimed at streamlining the review and approval procedures for innovative drugs and medications urgently needed in clinical settings. Hong Kong's endeavors to foster medical innovation are in perfect harmony with this national blueprint, with the ambitious vision of transforming the city into a global epicenter for medical innovation. To realize this vision, Hong Kong must bolster its clinical trial capacities, and the Guangdong-Hong Kong-Macao Greater Bay Area International Clinical Trial Institute is poised to play a pivotal role as a driving force. Furthermore, the SAR government is set to accelerate the implementation of the '1+' new drug approval mechanism, experimenting with priority approval pathways for innovative drugs. It also plans to establish the Hong Kong Drug and Medical Device Supervisory and Administrative Center within the current year, aiming to refine the approval system and thereby fuel the growth and market expansion of the medical and health sector.